NovaBridge Biosciences

03/18/2026 | Press release | Distributed by Public on 03/18/2026 19:40

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Lei Ming Kyler
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [NBP]
(Last) (First) (Middle)
C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
ROCKVILLE, MD 20850
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
2025 Employee Share Option (right to buy) (3) 10/16/2035 Ordinary Shares(1) 996,775(2) $4.25(2) D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Lei Ming Kyler
C/O NOVABRIDGE BIOSCIENCES,
2440 RESEARCH BOULEVARD, SUITE 400
ROCKVILLE, MD 20850
Chief Financial Officer

Signatures

/s/ Xi-Yong (Sean) Fu as attorney-in-fact 03/18/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
(2) Number of underlying securities and exercise price expressed in terms of ADSs.
(3) The option was granted on October 16, 2025. The option vests and becomes exercisable over five years, with four-tenths vesting on the second anniversary of the grant date and the balance vesting ratably on each subsequent anniversary of the grant date.

Remarks:
Exhibit List: Ex. 24.1 - Power of Attorney
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
NovaBridge Biosciences published this content on March 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 19, 2026 at 01:40 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]